GW Pharmaceuticals plc announces changes to Board of Directors

GW also announces that James Noble, appointed on 25 January 2007 as senior independent director, has assumed the newly created position of Deputy Chairman.

GW previously announced in its 2006 preliminary results statement that the Board has over recent months been carrying out a corporate governance review process with regard to the proportion of independent non-executive directors. The first step in this review process was the appointment of James Noble and the decision of David Mace to retire at this year's AGM. Today's announcement completes this current review process.

Richard Forrest is currently a non-executive director of Alizyme plc, and has extensive commercial experience in the international pharmaceutical industry, gained over a period of 30 years. This included 19 years with the Rhone-Poulenc Rorer Group (now Sanofi-Aventis), where his most senior position was Senior Vice-President, Europe. His roles have included responsibility for General Management, Marketing and Sales and Business Development in Europe and Rest of the World (South America, Africa, Middle East and South-East Asia). He was also a member of the Pharmaceutical Operations Committee which had responsibility for worldwide operational performance, as well as the Pharmaceutical Development Committee, which had responsibility for all R&D portfolio decisions and major licensing. Subsequently, his most recent position was Chief Operating Officer of Novuspharma SpA, an Italian biopharmaceutical company, which merged with Cell Therapeutics Inc. in January 2004.

Dr Geoffrey Guy, Chairman of GW, said "The changes announced today significantly strengthen our Board and the resultant Board composition is now well suited to the next phase in the Company's development. We are delighted to welcome Richard to GW and to enhance James' role as Deputy Chairman."

Commenting on David Morrison, Dr Guy, said, "David has had a long association with GW as an investor, and most recently as a non-executive director. I should like to thank David for his long-standing support for GW and wish him continued success in his other business ventures."

Richard is currently a non-executive director of Alizyme plc. There are no further disclosures to be made in respect of Richard Forrest pursuant to paragraph (f) of Schedule 2 of the AiM Rules for companies.